 |  |  |  |  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| Interested in Clinical Trials? are you eligible? |
| LUPUS Clinical Trial HGS Benlysta ClinicalTrials.gov Protocol # HGS1006-C1113 for inclusion exclusion criteria Start: May 2013 - current A randomized, double-blind, placebo-controlled 52-week study to assess adverse events of special interest adults with active, autoantibody-positive Systemic Lupus Erythematosus (SLE) receiving Belimumab (Benlysta). 1) Male or Female > 18 years old (female subject Not pregnant or currently nursing, or plan on being pregnant within the next 5 years) 2) Diagnosis of SLE 3) Active, autoantibody positive SLE 4)Are on a SLE treatment regimen - corticosteroids and/or other immunomodulatory For more information, please call 925-413-1451 Tim Davis, Research Coordinator |
| AstraZeneca TULIP1 ClinicalTrials.gov Protocol # D3461C00005 for Inclusion Exclusion criteria Start: September 2015 - current A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systamic Lupus Erythematosis (LUPUS) Informed Consent (PDF-25 pages) Flyer for potential subjects (coming soon) 2-Page inclusion-exclusion criteria - for Providers For more information, please call 925-413-1451 Tim Davis, Research Coordinator |
| Axial Spondyloarthritis Clinical Trial Janssen Ustekinumab (Stelara) ClinicalTrials.gov Protocol # CNTO1275AKS3002 for inclusion exclusion criteria Start: December 2015 - Current A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis Informed Consent (PDF-38 pages) Flyer (3 fold- 2 page PDF) - for potential subjects 2 page inclusion-exclusion criteria - for Providers For more information, please call 510-791-1300 ask for Victor or Richelle, Research Coordinator |
|
| CONTACT US: Tel: 510-791-1300 Fax: 510-791-1301 3775 Beacon Ave, Suite 100, Fremont, CA 94538 |
| A Cross-sectional Observational Study Evaluating Clinical Specialty Setting as Determinant of Management in Patients with Psoriatic Arthritis (Start 2016 June- Dec) Informed Consent (9 pages) California Experimental Subject's Bill of Rights (1 page) Study #: H15-457 Sponsor: AbbVie Study Doctor: Barry Shibuya MD Qualification: You have either been diagnosed in the past with psoriatic Arthritis (PsA), suspected to have PsA or newly diagnosed with PsA. Note: this study does not replace your regular medical care. Purpose of the Study The purpose of this study is to evaluate the role of different physician specialties (Rheumatologist, Dermatologist, and Primary Care Physician) in the management of PsA. This study is being conducted at approximately 60 research centers in the US. Approximately 1040 patients with suspected or newly diagnosed PsA or PsA diagnosed in the past will participate in this study. Your participation in this study will consist of 2 study visits. You will have one visit at a Rheumatology research center and one visit at a Dermatology research center. Your participation in the study will last approximately 6 weeks but could be longer depending on the time to complete PsA diagnostic testing and the availability of the study doctor for the second visit. For more information, please call 510-791-1300 ask for Victor or Richelle, Research Coordinator |
| Fremont Rheumatology Arthritis, Osteoporosis, and Auto-Immune Diseases Barry Shibuya M.D. and Christine Elias M.D. |